1. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells
    YUKIE YOSHII et al, 2016 CrossRef
  2. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance
    David J. Monsma et al, 2014, Pediatr Blood Cancer CrossRef
  3. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells
    Judith Niesen et al, 2015, J Cancer Res Clin Oncol CrossRef
  4. null
    Stephan Lindsey et al, 2015 CrossRef
  5. Targeting protein kinases to reverse multidrug resistance in sarcoma
    Hua Chen et al, 2016, Cancer Treatment Reviews CrossRef
  6. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
    Maximilian M. L. Knott et al, 2020, Cancer Metastasis Rev CrossRef
  7. Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
    Kristy Pilbeam et al, 2018, Oncotarget CrossRef
  8. Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma
    Anke E.M. van Erp et al, 2018, Mol Cancer Ther CrossRef
  9. HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
    Carla De Giovanni et al, 2021, Cells CrossRef
  10. Autoantibody profiling of alveolar rhabdomyosarcoma patients unveils tumor-associated antigens with diagnostic and prognostic significance
    Elena Poli et al, 2021, OncoImmunology CrossRef
  11. Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors
    Wen-I Chang et al, 2022, Front. Pharmacol. CrossRef
  12. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
    Marina Ferreira Candido et al, 2023, Pharmaceutics CrossRef